Sodium Sulfobutyl-β-Cyclodextrin: Unlocking Poorly Soluble Drug Delivery, Empowering High-End Formulation Innovation

I. Cutting-Edge Molecular Strength, Reshaping New Possibilities for Drug Delivery

•      Ultra-high solubilization efficiency: stably forms inclusion complexes with neutral, cationic, and anionic drugs, increasing the solubility of poorly soluble drugs by 10–25,000 times,         thoroughly solving the industry challenge of lipophilic drugs being insoluble in water.
•      High biosafety: extremely low hemolytic activity, significantly better renal safety than ordinary cyclodextrins, rapidly cleared by the kidneys in vivo with no accumulation risk, meeting        injection-grade pharmaceutical standards.
•     Strong stability protection: isolates drugs from light, oxygen, and enzymatic degradation, extends shelf life, and improves storage stability.
•     Precise delivery control: enables controlled and sustained drug release, masks bitter taste, reduces irritation, and adapts to various administration routes.

II. Full-Scenario Applications, Covering the Whole Field of Pharmaceutical Preparations

1. Core excipient for injections
       Supports the launch of anti-infective and anti-tumor injections such as voriconazole, docetaxel, and remdesivir, replacing traditional toxic co-solvents, reducing sensitization risks, and ensuring clinical safety.
2. Oral formulation upgrading
       Improves dissolution and bioavailability of drugs such as danazol and flunarizine, masks unpleasant odors, and optimizes patient experience.
3. Special administration routes
       Suitable for nasal and ophthalmic preparations, enhances mucosal permeability, promotes efficient absorption, and enables local targeted therapy.
4. Carrier for innovative drug R&D
       Acts as a stabilizer and inclusion carrier for mRNA vaccines, targeted drugs, and biological products, supporting cutting-edge pharmaceutical breakthroughs.

III. Compliant & High-Quality, Supporting Successful Formulation Approval

• Purity ≥99.0%, degree of substitution precisely controlled at 6.2–6.9, excellent batch-to-batch consistency;
•    Heavy metals ≤5 ppm, bacterial endotoxins meet injection-grade requirements, and microbial limits are qualified;
•    Supports CDE registration and filing, suitable for innovative drug applications and generic drug consistency evaluation, safeguarding pharmaceutical R&D.

IV. Choose Sodium Sulfobutyl-β-Cyclodextrin to Seize the Opportunity in Formulation R&D